Filament Health Announces Interim Results From Phase I Clinical Trial At The University Of California San Francisco
Healthy subjects have been dosed with Filament’s botanical psilocybin and psilocin drug candidates VANCOUVER, BC — Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”or the “Company”), a clinical‐stage natural psychedelic drug development… Read More




